Table 1 Baseline characteristics by treatment group and study at day 0. Means are arithmetic. CQ = chloroquine, SP = sulphadoxine-pyrimethamine, AS1 = 1-dose artesunate, AS-3 = 3-dose artesunate, AL = artemether-lumefantrine (Coartem), AQ = amodiaquine.
Study & country | Treatment | N | Parasitology follow up days (bold = transmission experiment) | Mean age (years) | Mean asexual parasite density/μl | Mean slide- positive gametocyte prevalence (%) | Mean gametocyte density/μl |
|---|---|---|---|---|---|---|---|
1. Gambia Targett 2001 [22] | CQ | 135 | 4, 7,14,28 | 5.9 | 80,886 | 2.5 | 33 |
| Â | SP | 277 | Â | 6.0 | 73,742 | 5.6 | 13 |
| Â | SP-AS1 | 113 | Â | 6.2 | 23,147 | 10.7 | 10 |
| Â | SP-AS3 | 74 | Â | 6.3 | 26,567 | 13.4 | 88 |
| Â | all | 599 | Â | 6.0 | 59,581 | 6.9 | 26 |
2. Gambia Targett 2001 [22] | SP | 101 | 7,14 | 4.4 | 28,684 | 6.0 | 31 |
| Â | SP-AS3 | 404 | Â | 4.8 | 27,738 | 8.0 | 127 |
| Â | all | 505 | Â | 4.7 | 27,927 | 7.6 | 107 |
3. Gambia Drakeley 2004 [20] | CQ | 129 | 3, 7,14,28 | 4.7 | 64,329 | 20.2 | 10 |
| Â | CQ-AS | 386 | Â | 4.8 | 66,593 | 20.2 | 22 |
| Â | all | 515 | Â | 4.8 | 66,026 | 20.2 | 19 |
4. Gambia Hallett 2006 [13] | CQ | 125 | 3, 7, 10, 14,28 | 4.5 | 63,640 | 21.6 | 30 |
| Â | SP | 180 | Â | 4.5 | 58,128 | 23.2 | 47 |
| Â | CQ-SP | 193 | Â | 4.6 | 79,900 | 19.2 | 37 |
| Â | all | 498 | Â | 4.6 | 68,009 | 21.2 | 39 |
5. Gambia Sutherland 2005 [21] | CQ-SP | 89 | 7,14,28 | 4.3 | 56,444 | 4.5 | 5 |
| Â | AL | 400 | Â | 4.4 | 57,550 | 6.3 | 9 |
| Â | (Coartem) | Â | Â | Â | Â | Â | Â |
| Â | all | 489 | Â | 4.3 | 57,347 | 6.0 | 9 |
6. Kenya Bousema 2006 [19] | SP | 152 | 3,7, 14,28 | 3.4 | 19,044 | 20.9 | 7 |
| Â | SP-AQ | 127 | Â | 2.9 | 20,578 | 22.3 | 8 |
| Â | SP-AS3 | 174 | Â | 3.2 | 21,620 | 24.4 | 8 |
| Â | AL (Coartem) | 75 | Â | 4.0 | 21,178 | 24.6 | 6 |
| Â | all | 528 | Â | 3.3 | 20,565 | 22.9 | 7 |